Jeffery Michael Reddan

Mr. Jeffery Michael Reddan


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2018 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
JRJeffery Michael Reddan
Jeffery Michael Reddan
DWDavid White
David White
HMHelen Macpherson
Helen Macpherson
ASAndrew Scholey
Andrew Scholey
APAndrew Pipingas
Andrew Pipingas
Modifying nutritional intake through supplementation may be efficacious for altering the trajectory of cerebral structural decline evident with increasing age. To date, there have been a number of clinical trials in older adults whereby chronic supplementation with B vitamins, omega-3 fatty acids, or resveratrol, has been observed to either slow the rate of decline or repair cerebral tissue. There is also some evidence from animal studies indicating that supplementation with glycerophospholipids (GPL) may benefit cerebral structure, though these effects have not yet been investigated in adult humans. Despite this paucity of research, there are a number of factors predicting poorer cerebral structure in older humans, which GPL supplementation appears to beneficially modify or protect against. These include elevated concentrations of homocysteine, unbalanced activity of reactive oxygen species both increasing the risk of oxidative stress, increased concentrations of pro-inflammatory messengers, as well as poorer cardio- and cerebrovascular function. As such, it is hypothesized that GPL supplementation will support cerebral structure in older adults. These cerebral effects may influence cognitive function. The current review aims to provide a theoretical basis for future clinical trials investigating the effects of GPL supplementation on cerebral structural integrity in older adults.

31 October 2018 in Nutrition Research Reviews
Verified
Journal Article
Closed access
PDF file
JRJeffery Michael Reddan
Jeffery Michael Reddan
HMH. Macpherson
H. Macpherson
DWDavid White
David White
ASA. Scholey
A. Scholey
APA. Pipingas
A. Pipingas
The proportion of adults aged 60 years and over is expected to increase over the coming decades. This ageing of the population represents an important health issue, given that marked reductions to cerebral macro- and microstructural integrity are apparent with increasing age. Reduced cerebral structural integrity in older adults appears to predict poorer cognitive performance, even in the absence of clinical disorders such as dementia. As such, it is becoming increasingly important to identify those factors predicting cerebral structural integrity, especially factors that are modifiable. One such factor is nutritional intake. While the literature is limited, data from available cross-sectional studies indicate that increased intake of nutrients such as B vitamins (for example, B6, B12 and folate), choline, n-3 fatty acids and vitamin D, or increased adherence to prudent whole diets (for example, the Mediterranean diet) predicts greater cerebral structural integrity in older adults. There is even greater scarcity of randomised clinical trials investigating the effects of nutritional supplementation on cerebral structure, though it appears that supplementation with B vitamins (B6, B12 and folic acid) or n-3 fatty acids (DHA or EPA) may be beneficial. The current review presents an overview of available research examining the relationship between key nutrients or adherence to select diets and cerebral structural integrity in dementia-free older adults.

8 September 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
MNMadeleine Courtney Nankivell
Madeleine Courtney Nankivell
FRFranklin Rosenfeldt
Franklin Rosenfeldt
APAndrew Pipingas
Andrew Pipingas
MPMatthew Pase
Matthew Pase
JRJeffery Michael Reddan
Jeffery Michael Reddan
CSCon Stough
Con Stough
Background and Objective: With an increase in the number of older citizens in most Western countries, cognitive decline is becoming an increasingly significant issue. Numerous age-related metabolic and physiological changes, such as increased inflammation and oxidative stress, decreased adenosine triphosphate (ATP) production, poorer cardiovascular function, and reduced cerebral blood flow, have been implicated in cognitive decline, prompting research into interventions. Among these, Coenzyme Q10 (CoQ10), an antioxidant and metabolic stimulant, has shown promise in improving some of the underlying biological mechanisms of cognitive decline. However, not much is known about the efficacy of CoQ10 supplementation on cognition in the elderly. Therefore, the aim of this review is to explore the efficacy of CoQ10 supplementation on cognitive function. Methods: We conducted a review of animal studies and human clinical trials investigating the effect of CoQ10 supplementation on cognition in samples who were healthy or with specific diseases. Overall, twelve studies demonstrated improved cognitive function and two showed a reduction in oxidative stress in response to CoQ10 supplementation, either alone or in combination with other compounds. Out of eight human clinical trials in healthy subjects (n = 2) and disease states (n = 6), four showed evidence of a beneficial effect of CoQ10 supplementation on cognition, while two demonstrated an increase in cerebral blood flow. Disparity in the results of the clinical trials presented here is likely due to differing testing procedures, inconsistent use of cognitive assessments, and/or varying bioavailability of different preparations of CoQ10. Conclusions: There is some evidence to suggest that cognition and the biological mechanisms that regulate it are positively impacted by CoQ10 therapy. However, it is crucial to note that the literature presents mixed results, with many human clinical trials also reporting no benefit of CoQ10 supplementation on cognitive performance. To fully evaluate the benefits of CoQ10 on cognitive function in ageing and in neurodegenerative diseases, future studies are needed that target possible mechanisms and utilise a wider range of cognitive assessments.

5 May 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
APAndrew Pipingas
Andrew Pipingas
JRJeffery Michael Reddan
Jeffery Michael Reddan
Sarah GauciSarah Gauci
Sarah Gauci
LYLauren Young
Lauren Young
GKGreg Kennedy
Greg Kennedy
ASAndrew Scholey
Andrew Scholey
The use of omega-3 polyunsaturated fatty acid (ω-3 PUFA) supplements is increasingly common among middle-aged and older adults. Users of ω-3 PUFA supplements often report using such supplements to support cognitive health, despite mixed findings reported within the ω-3 PUFA literature. To date, very few studies have explored cognitive effects in distinctly middle-aged (40 to 60 years) adults, and none have examined the acute effects (in the hours following a single dose) on cognitive performance. The current study evaluated whether a single dose of ω-3 PUFA (4020 mg docosahexaenoic acid and 720 mg eicosapentaenoic acid) influences cognitive performance and cardiovascular function in middle-aged males. Cognitive performance and cardiovascular function were assessed before and 3.5–4 h after consumption of a high dose of ω-3 PUFA (DHA + EPA) or placebo, incorporated into a standardized meal (i.e., single serve of Greek yogurt). In this study of middle-aged males, no significant differential treatment effects were observed for cognitive performance. However, a significant reduction in aortic systolic blood pressure (pre-dose to post-dose) was apparent following consumption of the ω-3 PUFA (DHA + EPA) treatment (mean difference = −4.11 mmHg, p = 0.004) but not placebo (mean difference = −1.39 mmHg, p = 0.122). Future replication in a sample comprising females, as well as patients with hypertension, is merited.

3 December 2024 in British Journal of Nutrition
Verified
Journal Article
Open access
PDF file
JRJeffery Michael Reddan
Jeffery Michael Reddan
Sarah GauciSarah Gauci
Sarah Gauci
LYLauren M. Young
Lauren M. Young
GKGreg Kennedy
Greg Kennedy
RRRenee Rowsell
Renee Rowsell
APAndrew Pipingas
Andrew Pipingas
While there is evidence that long-chain n -3 PUFA supplementation benefits mood, the extent to which a single high dose of n -3 PUFA can induce acute mood effects has not been examined. The present study investigated whether a single dose of a DHA-rich powder affects self-reported mood in middle-aged males during elevated cognitive demand. In a randomised, double-blind, placebo-controlled trial with a balanced crossover design, twenty-nine healthy males (age M = 52.8 years, sd = 5.3) were administered a powder (in a meal) containing 4·74 g n -3 PUFA (DHA 4020 mg; EPA 720 mg) or placebo in random order on two different testing days separated by a washout period of 7 ± 3 d. Participants completed mood assessments before and after completing two cognitive test batteries at baseline and again 3·5–4·0 h following the consumption of the active treatment or placebo. While completion of the cognitive test batteries increased negative mood, differential effects for alertness ( P = 0·008) and stress ( P = 0·04) followed consumption of the DHA-rich powder compared with placebo. Although alertness declined when completing the cognitive batteries, it was higher following consumption of the DHA-rich powder compared with placebo ( P = 0·006). Conversely, stress was lower following consumption of the DHA-rich powder relative to placebo, though this difference only approached significance ( P = 0·05). Overall, results from this pilot study demonstrate that a single high dose of n -3 PUFA may deliver acute mood benefits following elevated cognitive demand in healthy middle-aged males.

27 June 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
MNMadeleine Courtney Nankivell
Madeleine Courtney Nankivell
FRFranklin Rosenfeldt
Franklin Rosenfeldt
JRJeffery Michael Reddan
Jeffery Michael Reddan
Judy B De HaanJudy B De Haan
Judy B De Haan
CPCherry Zhang Ping
Cherry Zhang Ping
CSCon Stough
Con Stough
Older age is typically characterized by decrements in cognitive performance relative to younger adults, though it may not necessarily reach clinical impairment. Dietary supplementation with ubiquinol, the reduced form of the antioxidant and cellular energizer CoQ10, may support cognitive function in older individuals. In the current randomized clinical trial of 111 adults aged 60 years and older (ubiquinol, n = 61; placebo, n = 50), 90 days of ubiquinol (200 mg) supplementation resulted in plasma CoQ10 levels being four times that of the placebo group at study end (p < 0.001). We found that ubiquinol supplementation did not facilitate group differences (controlling for baseline values and relevant demographics) in cognitive function, blood biomarkers reflective of oxidative stress or inflammation, measures of cardiovascular health, or subjective mood at study end. However, regression analyses revealed a positive association between change in plasma CoQ10 and memory performance, as well as a negative association between change in oxidative stress and memory performance at study end in those who received ubiquinol but not placebo. We conclude that adequately powered future clinical trials should examine whether long-term supplementation with ubiquinol can support cognitive function in older adults at risk of cognitive decline or with health conditions predisposing them to risk factors associated with decline.